Among 2 analysts covering Steelcase (NYSE:SCS), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Steelcase had 7 analyst reports since September 1, 2015 according to SRatingsIntel. The firm earned “Strong Buy” rating on Thursday, March 23 by Raymond James. The rating was downgraded by Sidoti on Wednesday, September 20 to “Hold”. Raymond James maintained the shares of SCS in report on Friday, June 23 with “Strong-Buy – Outperform” rating. The firm has “Buy” rating by Zacks given on Tuesday, September 1. Raymond James downgraded Steelcase Inc. (NYSE:SCS) on Wednesday, December 23 to “Mkt Perform” rating. The stock of Steelcase Inc. (NYSE:SCS) earned “Buy” rating by Sidoti on Friday, September 1. The firm earned “Neutral” rating on Friday, November 4 by Seaport Global. See Steelcase Inc. (NYSE:SCS) latest ratings:
20/09/2017 Broker: Sidoti Rating: Hold New Target: $16.0 Downgrade
01/09/2017 Broker: Sidoti Rating: Buy New Target: $16.0 Upgrade
The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a huge mover today! The stock decreased 0.73% or $0.11 during the last trading session, reaching $14.97. About 791,055 shares traded. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 12.45% since February 23, 2017 and is uptrending. It has underperformed by 4.25% the S&P500.The move comes after 9 months negative chart setup for the $2.78 billion company. It was reported on Feb, 23 by Barchart.com. We have $14.37 PT which if reached, will make NASDAQ:FOLD worth $111.16M less.
Since October 12, 2017, it had 0 insider purchases, and 16 selling transactions for $11.04 million activity. On Tuesday, January 2 the insider Quimi Daphne sold $117,723. The insider Baird William D III sold $570,132. 5,000 shares were sold by Barth Jay, worth $73,559. Crowley John F sold $1.06 million worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Tuesday, October 17. $147,191 worth of stock was sold by Andrews Kurt J. on Tuesday, January 2. RAAB MICHAEL also sold $140,490 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Tuesday, January 2. Do Hung also sold $715,360 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares.
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company has market cap of $2.78 billion. The Company’s principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. It currently has negative earnings. The firm is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease.
Analysts await Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report earnings on March, 7. They expect $-0.31 earnings per share, up 3.13% or $0.01 from last year’s $-0.32 per share. After $-0.41 actual earnings per share reported by Amicus Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -24.39% EPS growth.
Among 9 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Amicus Therapeutics had 22 analyst reports since August 18, 2015 according to SRatingsIntel. The rating was upgraded by Janney Capital to “Buy” on Tuesday, March 8. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Buy” rating by Chardan Capital Markets on Monday, October 5. The firm has “Overweight” rating given on Tuesday, September 8 by JP Morgan. Robert W. Baird maintained the stock with “Buy” rating in Wednesday, February 7 report. Cowen & Co maintained it with “Buy” rating and $1200 target in Sunday, June 25 report. The firm has “Outperform” rating given on Wednesday, July 12 by Robert W. Baird. On Wednesday, March 30 the stock rating was initiated by Goldman Sachs with “Neutral”. The company was upgraded on Tuesday, January 24 by Robert W. Baird. The rating was maintained by Leerink Swann on Monday, October 5 with “Outperform”. As per Tuesday, August 18, the company rating was downgraded by Zacks.
Investors sentiment increased to 2.33 in Q3 2017. Its up 1.10, from 1.23 in 2017Q2. It increased, as 16 investors sold Amicus Therapeutics, Inc. shares while 32 reduced holdings. 52 funds opened positions while 60 raised stakes. 192.70 million shares or 14.18% more from 168.77 million shares in 2017Q2 were reported. Credit Suisse Ag has invested 0.01% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Hightower Advsr Llc invested in 28,063 shares. Dekabank Deutsche Girozentrale owns 70,900 shares or 0.01% of their US portfolio. Venbio Select Advisor Ltd Liability, a California-based fund reported 6.44 million shares. Columbus Circle Investors, a Connecticut-based fund reported 199,874 shares. Creative Planning has 10,343 shares for 0% of their portfolio. Northern Tru accumulated 1.98 million shares. Nicholas Investment Ptnrs Limited Partnership reported 134,388 shares. Td Asset Mngmt owns 225,454 shares for 0.01% of their portfolio. California Employees Retirement Sys holds 181,000 shares. Teacher Retirement Of Texas reported 12,048 shares stake. One Trading Lp has invested 0.04% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Ghost Tree Capital Ltd Llc stated it has 200,000 shares or 0.64% of all its holdings. Prudential Financial Incorporated holds 0.01% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 467,900 shares. Invesco Ltd holds 0% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 59,142 shares.
Steelcase Inc. manufactures and sells integrated portfolio of furniture settings, user-centered technologies, and interior architectural products. The company has market cap of $1.68 billion. The firm operates through Americas, EMEA, and Other Category divisions. It has a 16.24 P/E ratio. The Company’s furniture systems portfolio comprises panel and freestanding furniture systems, storage, desks, benches, tables, and complementary products, such as worktools.
Since January 4, 2018, it had 0 insider buys, and 1 insider sale for $201,296 activity. On Thursday, January 4 the insider WEGE PETER M II sold $201,296.
The stock decreased 0.69% or $0.1 during the last trading session, reaching $14.45. About 70,874 shares traded. Steelcase Inc. (NYSE:SCS) has risen 11.15% since February 23, 2017 and is uptrending. It has underperformed by 5.55% the S&P500.